During the past decade, cardiac magnetic resonance has gained increasing popularity in the diagnosis of hypertrophic cardiomyopathy because of its greater accuracy and better characterization of cardiac morphology compared with other imaging modalities. In this pictorial essay, a global clinical portrait of hypertrophic cardiomyopathy will be drawn. The various radiologic findings associated with each variant of hypertrophic cardiomyopathy, and the clinical edge offered by cardiac magnetic resonance will be discussed.
Cardiovascular magnetic resonance (CMR) has proved to be a useful tool for assessing a hypertrophic heart, especially when echocardiography is inconclusive or suboptimal. In this article, we review the pathology of hypertrophic cardiomyopathy (HCM), including etiology; clinical manifestation; physiopathology; different phenotypes and implication; management; diagnostic imaging workup; the advantages and disadvantages of ultrasound and CMR; specific information provided by CMR for clinical management; and CMR differentiation of HCM from other cardiomyopathies.
What Is HCM?
Definition
The generally accepted clinical definition of HCM is a left ventricular (LV) hypertrophy associated with a nondilated ventricular chamber that cannot be explained by a cardiac or a systemic disease, including abnormal loading conditions [1, 2] . HCM is a relatively common genetic cardiac disease, with a prevalence in the general population estimated at approximately 1:500 [3] . In young people, including children and athletes, it is the most common cause of sudden death [4, 5] . In adults of all ages, HCM can present as refractory dyspnea, angina, syncope, palpitation and heart failure. Nonetheless, annual mortality rates are approximately 1%, and almost 25% of these patients have preserved longevity [1, 2, 6] .
Etiology
Hypertrophic cardiomyopathy is caused by mutations in genes that encode cardiac sarcomere proteins [7] . It is inherited in an autosomal-dominant fashion, with variable expression and penetrance. A thick LV wall is the general morphologic phenotype. However, because of variable gene mutations and variable transmission, cardiac involvement can vary and rarely presents with a normal LV thickness or a right side involvement. The wide range of genetic expression can also affect the age of presentation. Although it usually presents in the pediatric population, some phenotypes can present in adulthood [2, 7] .
Physiopathology and Clinical Consequences
The physiopathologic consequences, depending on the distribution and the degree of myocardial thickening, may be obstruction, arrhythmia predisposition, cardiac dysfunction, aneurysmal formation, or embolic disease [2, 5] . Obstructive diseases are divided into subaortic or mid ventricular [7] . When the thickening involves the interventricular septum near the LV outflow tract (LVOT), it will create turbulent flow. Consequently, the anterior leaflet of the mitral valve may have a systolic anterior motion that causes contact with the septum, which contributes to outflow obstruction ( Figure 1) [2, 5, 7, 8] . Hypermobility of the papillary muscles or an unusual orientation of papillary muscles (anteroapical displacement and bifid muscle) are other notable causes of subaortic obstruction in HCM and can account for obstruction even in patients with nearnormal maximal wall thickness (MWT) [9] . LVOT obstruction produces typical symptoms of dyspnea, angina, or syncope on exertion. To determine whether or not the LVOT thickening is obstructive, a pressure gradient can be calculated with the modified Bernoulli equation: pressure gradient ¼ 4 Â Vmax 2 . The cutoff value of 30 mm Hg is now generally accepted [9, 10] . Patients with an LVOT gradient higher than 30 mm Hg show a higher risk of heart failure, atrial fibrillation, stroke, and sudden death [6, 9, 10] . Patients may have a normal LVOT gradient at rest, and the obstruction is often detected by using provocative maneuvers, such as exercise, Valsalva maneuver, or pharmacologic provocation [2, 5, 10] . The other form of obstruction is mid ventricular, which occurs when there is apposition of a hypertrophic portion of the wall to another part of the LV chamber during systole. In this context, an apical aneurysm may develop [11] .
Aside from obstruction, symptoms of cardiac insufficiency may occur secondary to diastolic dysfunction of the hypocontractile muscle [2, 5, 10] . Over time, with scarring, systolic dysfunction may also develop. When there is an obstruction, diastolic dysfunction, or atrial enlargement, blood stagnation and clot formation may lead to cardioembolic stroke [5, 10] . With myocardial disarray and interstitial fibrosis, regions of hypertrophied cardiac muscle fail to conduct electricity in a normal way. Heart block or a re-entrant circuit that leads to sustained or nonsustained ventricular arrhythmia can be created [2] .
Different Phenotypes
Although there is no consensual classification of the various phenotypes of HCM, a largely used nomenclature distinguishes among asymmetric septal, apical, mid ventricular, masslike, and symmetric (concentric) hypertrophy. A last phenotype seen in end-stage disease, the ''burned-out phase,'' also is described [7, 9, 11] .
Asymmetric septal HCM
Asymmetric septal hypertrophy is by far the most common phenotype, with an estimated incidence of 80% [7] . The anteroseptal wall is usually involved, with a localized thickening of the septum. LVOT obstruction is detected in up to 30% of these patients [9] . Patients may have a normal LVOT gradient at rest, and the obstruction often is detected by using provocative maneuvers, such as exercise or the Valsalva maneuver, or by using pharmacologic provocation. Typical symptoms of dyspnea, angina, or syncope on exertion will orient the clinician towards an obstructive disease. The mitral valve is frequently abnormal in these patients. Elongation of the anterior leaflet or both leaflets and secondary mitral regurgitation are common. Mitral regurgitation is also highly associated with left atrial enlargement and with an increased risk of cardiovascular events and diastolic dysfunction [10] . In turn, elongation of mitral leaflets can lead to systolic anterior motion. Patients with this phenotype may benefit from interventional procedures (discussed in the Management section).
Apical HCM
Apical hypertrophy is an asymmetric form in which there is an apical wall thickening. It represents 9% of cases and has a good prognosis, with a rare incidence of sudden death [7, 11] . Apical aneurysm can occur and is better detected by using magnetic resonance imaging ( Figure 2 ) [12] .
Mid ventricular HCM
Mid ventricular hypertrophy is a variant of asymmetric hypertrophy but is much less frequent (4%) [7] . It involves the middle third portion of the LV and may result in severe obstruction. Apical aneurysm is a common finding in this variant and is thought to be secondary to increased systolic pressure, especially in obstructive cases. This type of HCM has a higher rate of ventricular tachycardia, necrosis, and systemic cardioemboli ( Figure 3 ) [11] .
Masslike HCM
Masslike hypertrophy is a rare (<2%) asymmetric hypertrophy that presents as a single mass within the myocardium [7] . The difference between masslike HCM and myocardial masses caused by other conditions, such as neoplasia, infiltrative states, and lymphoma, is a signal intensity that parallels the signal of the uninvolved myocardial segment before and after gadolinium administration as well as a relative preservation of myocardial contractility. Those 2 features are unlikely in other conditions in which signals vary and contraction is absent ( Figure 4 ) [2, 11] . This will be reviewed in the differential diagnosis section.
Symmetric (concentric) HCM
Symmetric (concentric) hypertrophy is a phenotype in which the ventricular wall is circumferentially thickened ( Figure 5 ). It represents approximately 6% of cases [7] . This appearance can be seen in various systemic conditions, which may be confused with HCM, such as infiltrative diseases (sarcoidosis, amyloidosis, and Fabry disease), athletic heart, and a secondary hypertrophy from chronic hypertension or aortic stenosis [2, 11, 13] .
Burned-out phase
In this phase of the disease, the LV is extensively replaced by fibrotic tissue. It is dilated and thin ( Figure 6 ) [8, 11] . Only a small number of patients evolve to this end-stage phase, and they usually are severely symptomatic and resistant to medical management. At this end-stage phase, cardiac dysfunction is not only diastolic but has progressed to systolic dysfunction, and cardiac transplantation might be considered.
Management
The symptoms of HCM can be treated medically, surgically, and with an implantable cardioverter defibrillator. Cardiac transplantation is the definitive treatment for terminal disease. Medical therapy consists of b-blocking agents, disopyramide and non-dihydropiridine calcium channel blockers. Angiotensin-converting-enzyme inhibitors are used for patients with systolic dysfunction [14] . Surgery aims at septal reduction for patients with severe drug-refractory symptoms (New York Heart Association class 3 or 4). Patients with asymmetric septal HCM are good candidates for this myomectomy or for alcohol septal ablation because it relieves the subvalvular obstruction. The myomectomy technique consists of septal slice resection by using a transaortic approach under the transthoracic echocardiography (TTE) view. The alcohol septal ablation technique consists of iatrogenic ethanol-induced focal necrosis of the hypertrophied septum and is performed percutaneously (Figure 7 ) [2] . The choice of either technique is determined by septal thickness, mitral valve morphology, and papillary muscle abnormality, as well as age and center expertise [14] .
An implantable cardioverter defibrillator is a reasonable option for patients for whom septal reduction would be suboptimal, for patients with a first-degree family history of sudden death and for patients with an MWT equal to or larger than 30 mm [14] . Otherwise, all patients with HCM and with prior documented cardiac arrest or significant arrhythmias (such as ventricular fibrillation or ventricular tachycardia) should have an cardioverter defibrillator. Heart transplantation is reserved for patients with end-stage heart failure and with no obstructive HCM and with an ejection fraction less than 50% as well as for children who are not candidates for the conventional care [14] .
Cardiac Magnetic Resonance Imaging: A New Criterion Standard?

Diagnostic Imaging Workup
This section will discuss the diagnostic approach to HCM, advantages and disadvantages of ultrasound and CMR, the specific information that CMR provides for clinical management, and the differentiation of HCM from other mimicking disorders. In suspected cases, workup begins with a clinical story, a family history, a physical examination, and an electrocardiogram. After that, imaging plays an important role in the initial evaluation of HCM. The generally accepted diagnostic criteria for HCM consists of a diastolic LV MWT equal to or larger than 15 mm. However, as previously discussed, mutant sarcomere genes have a variable expression and penetration. LV can thus be associated with any wall thickness [5] , which implies that a normal LV thickness does not exclude a diagnosis of HCM, especially if there is a high pretest probability [3] . In those cases, the role of genetic testing is of great interest, but only 50% of cases have an identifiable mutation [7] .
Advantages and Disadvantages of Modality
Traditionally, 2-dimensional and M-mode transthoracic echocardiography has been the preferred imaging technique for the initial evaluation of patients with suspected HCM [7] . Although it provides useful information on cardiac and valvular morphology as well as dynamic functions, it is operator dependent, limited to patients who are echogenic, and fails to detect anterolateral and apical HCM in up to 10% of cases, even with the use of contrast [2, 7, 9, 15] . In the past decades, ultrasound has been supplanted by the advent of CMR. This modality has better soft tissue resolution and better contrast between blood and myocardium. It allows a much more accurate characterization of heart volumes and functions, tissue morphology, and distribution of myocardial hypertrophy [1, 16] . It also makes it possible to exclude other disease entities that could perhaps mimic HCM with other imaging modalities [2, 13, 17] . Cardiac imaging resonance can also detect features related to sudden death, apical aneurysms, and clots, and it provides new information for prognosis stratification, which helps in treatment planning. Finally, this modality is easily reproducible and comparable for follow up, which can be safely performed for patients at high risk and who have not yet developed the morphology and who have negative genetic tests [2] .
Specific Information Imaging Provided by CMR for Clinical Management
When performed with gadolinium administration, CMR offers a unique clinical edge in identifying patients at higher risk of adverse cardiovascular events. By using an inversion recovery pulse sequence for late gadolinium enhancement (LGE), CMR can detect interstitial fibrosis, myocardial disarray, and macroscopic scarring, with a good location and extent correlation to histopathologic studies [8, 18] . The physiopathology of these changes present in 80% of patients with HCM is not fully understood, but there is an hypothesis of supply-demand mismatch in the hypertrophied myocardium [16] .
There are multiple clinical implications of myocardial fibrosis detection. The extent of myocardial fibrosis correlates with progressive disease, New York Heart Association status and sudden cardiac death risk factors, such as nonsustained ventricular tachycardia, an MWT equal to or larger than 30 mm, and the presence of multiple risk factors [18] . A positive LGE study is associated with LV dilatation and an ejection fraction of less than 50% [1, 16, 18] . In terms of clinical impact, it is reasonable to assume that myocardial fibrosis is a substrate for arrhythmias such as ventricular tachyarrhythmia and atrial fibrillation [8] . Finally, it is possible to differentiate microvascular ischemic disease due to HCM from myocardial infarction based on the pattern and extent of LGE ( Figure 8 ) [16] .
The association among an MWT larger than or equal to 30 mm, sudden cardiac death, and death related to heart failure has been demonstrated [12, 19] . However, the positive predictive value of sudden death in patients with HCM and an MWT of 30 mm or more is only 13%; similarly, people who died suddenly had HCM in 16% of cases [12] , which highlights the importance of considering other classic clinical factors that increase the risk of sudden death (Table 1 ) [13] . The importance of these clinical risk factors is such that, even with a normal MWT (<15 mm), a patient with 2 risk factors has a 5-year survival rate comparable with someone with an MWT larger than 30 mm and no risk factor (Table 1 ) [13] . Therefore, the presence or absence of a significant myocardial hypertrophy alone does not predict outcome.
Differential Diagnosis Consideration
The difference between HCM and other causes of hypertrophy (symmetric or asymmetric) is more accurately established with CMR (Table 2) [2, 8] . The differential diagnosis includes infiltrative disease (amyloidosis, sarcoidosis, and Fabry disease), tumour, athletic heart, and secondary hypertrophy. Key radiologic features that allow discrimination are the following: involvement distribution, signal intensity, contractile activity, late gadolinium enhancement pattern (LGE), and another diagnosis (aortic stenosis).
In HCM, the thickened zone produces a signal intensity that parallels the normal cardiac muscle signal. The LGE pattern is typically mesocardial, and, on dynamic sequences, there is decreased contractility [2, 7, 8, 11, 20] . In infiltrative diseases, the involvement is diffuse, potentially affecting the right ventricle and both atria. In addition, the signal intensity may differ from that of the muscle. In amyloidosis, the signal intensity has a hyposignal in both T1 and T2 sequences, and, in inflammatory involvement (sarcoidosis, Wegener), there is a T2 hypersignal in the granulation zone that represents oedema [2, 13, 21] . Characteristic LGE patterns differ for different diseases. Amyloidosis gives a biventricular circumferential subendocardial enhancement called the ''zebra pattern'' on LGE sequences [2, 20, 21] . Sarcoidosis gives a LGE pattern that can be nodular, subendocardial, or transmural (in chronic cases), and correlates with the T2-hypersignal of granulation oedema [2, 13, 21] . Kinetic studies show that infiltrative diseases have decreased contractility, whereas athletic heart have normal function. Athletic heart is considered a nonpathologic condition, often diagnosed by using clinical information of high exercise activity, and a ratio of diastolic wall thickness to LV enddiastolic volume corrected to a body surface value of less than 0.15 mm/m 2 /mL [2, 5] . LGE disease patterns are presented in Table 3 . 
